A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
StoppedRecruitment suspendedSponsor's reason: Other - evaluation of patients currently enrolled on study
Study sites: 128 to 129
MinorSite details revised at 1 of 128 sites
MinorSite details revised at 1 of 128 sites
MinorSite details revised at 2 of 128 sites
MinorSite details revised at 1 of 128 sites
Show 22 earlier versionsHide 22 earlier versions
MinorStudy sites: 127 to 128
MinorEligibility criteria shortened, about 8 words
Site details revised at 75 of 127 sites
MinorSite details revised at 1 of 127 sitesv405
MinorSite details revised at 1 of 127 sitesv404
MinorSite details revised at 1 of 127 sitesv403
MinorSite details revised at 1 of 127 sitesv402
MinorSite details revised at 1 of 127 sitesv401
MinorSite details revised at 2 of 127 sitesv400
MinorSite details revised at 1 of 127 sitesv399
MinorSite details revised at 2 of 127 sitesv398
MinorSite details revised at 2 of 127 sitesv397
MinorSite details revised at 4 of 127 sitesv396
MinorSite details revised at 2 of 127 sitesv395
MinorSite details revised at 1 of 127 sitesv394
MinorSite details revised at 1 of 127 sitesv393
MinorSite details revised at 1 of 127 sitesv392
MinorSite details revised at 1 of 127 sitesv391
MinorSite details revised at 2 of 127 sitesv390
MinorSite details revised at 1 of 127 sitesv389
MinorSite details revised at 1 of 127 sitesv388
MinorRe-verified, no change to tracked fieldsv387
MinorSite details revised at 5 of 127 sitesv386
NotablePrimary endpoint(s) modified
Site details revised at 11 of 127 sites
v385
MinorStudy sites revised (127)v384
MinorSite details revised at 1 of 127 sitesv383
MinorSite details revised at 1 of 127 sitesv382
MinorSite details revised at 1 of 127 sitesv381
MinorSite details revised at 2 of 127 sitesv380
MinorStudy sites revised (127)v379
MinorSite details revised at 4 of 127 sitesv378
MinorSite details revised at 1 of 127 sitesv377
MinorSite details revised at 1 of 127 sitesv376
MinorSite details revised at 1 of 127 sitesv375
MinorSite details revised at 1 of 127 sitesv374
MinorSite details revised at 1 of 127 sitesv373
MinorSite details revised at 2 of 127 sitesv372
MinorStudy sites revised (127)v371
MinorSite contacts updated at 1 of 127 sitesv370
MinorSite details revised at 1 of 127 sitesv369
MinorSite details revised at 1 of 127 sitesv368
MinorSite details revised at 1 of 127 sitesv367
MinorSite details revised at 1 of 127 sitesv366
MinorSite details revised at 1 of 127 sitesv365
MinorSite details revised at 1 of 127 sitesv364
MinorSite details revised at 2 of 127 sitesv363
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.